Regulatory Hurdles Shape Philip Morris’s Pivot to Smoke-Free Products

Billions at Stake in FDA Review

The future trajectory of Philip Morris International hinges on critical regulatory determinations from the U.S. Food and Drug Administration concerning its smoke-free product portfolio. As the tobacco giant channels billions into alternative technologies, the FDA’s upcoming rulings will fundamentally influence marketing permissions for its IQOS heated tobacco system.

This week, Philip Morris presented fresh scientific evidence to the FDA’s Tobacco Products Scientific Advisory Committee regarding its IQOS heated tobacco apparatus. The central issue involves renewing the “Modified Risk Tobacco Product” designation, initially granted for a four-year term in 2020. This classification permits the company to market these products as presenting reduced harm compared to conventional cigarettes, a crucial commercial advantage.